Home /Research /Commentary: Neoadjuvant checkpoint inhibitors in resectable non–small cell lung cancer—Ready for prime time?
OTHER

Commentary: Neoadjuvant checkpoint inhibitors in resectable non–small cell lung cancer—Ready for prime time?

Boris Sepesi, Tina Cascone

Year
2019
Citations
2
Access
Open access

Keywords

MedicineImmunotherapyLung cancerOncologyChemotherapyInternal medicineCancerRadiation therapyClinical trial

Related papers

Browse all OTHER papers